ABBV

SEC source: 0001179110-20-005787 · edgar.xml · nonDerivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,487

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-20-005789 · edgar.xml · nonDerivative · entry 1

WADDELL FREDERICK H · CIK 0001223690 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,881

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-20-005791 · edgar.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,995

F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-20-005829 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,704

F1 · price: Received in exchange for 70 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020).

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 12

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,613

Underlying: Common Stock · 3,613 shares

Expires 2028-03-06

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

F6 · derivative.exercise_date: The options are exercisable as follows: 1,804 exercisable as of 5/8/2020; 902 as of 3/6/2021; and 907 as of 3/6/2022.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 11

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,440

Underlying: Common Stock · 3,440 shares

Expires 2027-03-06

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

F5 · derivative.exercise_date: The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 10

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,567

Underlying: Common Stock · 2,567 shares

Expires 2026-03-07

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 9

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,017

Underlying: Common Stock · 2,017 shares

Expires 2025-03-16

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 8

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,729

Underlying: Common Stock · 5,729 shares

Expires 2025-02-20

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 7

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,370

Underlying: Common Stock · 6,370 shares

Expires 2024-02-21

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 6

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,809

Underlying: Common Stock · 7,809 shares

Expires 2023-02-21

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 5

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,184

Underlying: Common Stock · 4,184 shares

Expires 2022-02-17

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · derivative · entry 4

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,184

Underlying: Common Stock · 4,184 shares

Expires 2021-08-05

F4 · security: Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303.

SEC source: 0001179110-20-005835 · edgar.xml · nonDerivative · entry 2

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,342

F2 · price: Received in exchange for 16,457 restricted stock units of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. restricted stock units was calculated pursuant to an equity award conversion ratio of 2.303. The restricted stock units vest as follows: 5,194 on 12/31/2020; 1,633 on 3/2/2021; 903 on 3/5/2021; 717 on 3/6/2021; 247 on 3/7/2021; 470 on 5/7/2021; 20,844 on 12/31/2021; 1,633 on 3/2/2022; 903 on 3/5/2022; 716 on 3/6/2022; 470 on 5/7/2022; 1,633 on 3/2/2023; 905 on 3/5/2023; and 1,635 on 3/2/2024.

SEC source: 0001179110-20-005835 · edgar.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,439

F1 · price: Received in exchange for 2,816 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020).

SEC source: 0001179110-20-005836 · edgar.xml · nonDerivative · entry 2

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,675

F2 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-20-005836 · edgar.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,342

F1 · price: Received in exchange for 2,983 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020).

SEC source: 0001179110-20-006518 · edgar.xml · nonDerivative · entry 2

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,675

F2 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-20-006518 · edgar.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,342

F1 · price: Received in exchange for 2,983 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020).

SEC source: 0001179110-20-005551 · edgar.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 4

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Step-son

Disclosed balance after: 5,900

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Step-daughter

Disclosed balance after: 5,900

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 17,615

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,092

SEC source: 0001179110-20-005099 · edgar.xml · nonDerivative · entry 2

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · In trust

Disclosed balance after: 48,500

F1 · balance_after: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.

SEC source: 0001179110-20-005099 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,006

SEC source: 0001179110-20-005098 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,491

SEC source: 0001179110-20-004513 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,110

Underlying: Common Stock · 90 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-20-004517 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,428

Underlying: Common Stock · 426 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-20-004520 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,530

Underlying: Common Stock · 446 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 3

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,844

SEC source: 0001179110-20-004512 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,892

SEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 3

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,844

F2 · date: This amendment is filed to correct the date of this transaction.

SEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 2

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,094

SEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 2

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,094

SEC source: 0001179110-20-005097 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,644

F1 · shares: This amendment is being filed to correctly indicate the number of shares purchased by the reporting person on March 20, 2020.

SEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,294

SEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,294

SEC source: 0001179110-20-003102 · edgar.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse in trust

Disclosed balance after: 2,875

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001179110-20-002851 · edgar.xml · nonDerivative · entry 1

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,224

SEC source: 0001179110-20-002852 · edgar.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,149

SEC source: 0001179110-20-002853 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,094

SEC source: 0001179110-20-002854 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,842

SEC source: 0001179110-20-002855 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,506

SEC source: 0001179110-20-002856 · edgar.xml · nonDerivative · entry 1

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,643

SEC source: 0001179110-20-002857 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,270

SEC source: 0001179110-20-002860 · edgar.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,445

SEC source: 0001179110-20-002861 · edgar.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,867

SEC source: 0001179110-20-002863 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,901

SEC source: 0001179110-20-002865 · edgar.xml · nonDerivative · entry 1

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,960